Austar Lifesciences (HKG:6118) expects a profit attributable to the owners between 15 million yuan and 20 million yuan in 2024, against an attributable loss of 113 million yuan logged for 2023, a Monday Hong Kong bourse filing said.
The company attributed the turnaround to a lack of loss from subsidiaries compared with a year ago, an increase in other income, and the group's organizational optimization.
Shares of the company closed nearly 2% higher on Tuesday.
Price (HKD): $0.57, Change: $+0.0100, Percent Change: +1.79%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。